INTS - NASDAQ

Intensity Therapeutics, Inc.

INTS·NASDAQ

$1.32

+3.9E+2%

HealthcareBiotechnology

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$62.24M

EPS-0.1300

P/E Ratio-0.57

Earnings Date11/12/2025

No Revenue Data

INTS has not reported any revenue values in the available annual periods.

-16.27M

Net Income

54%

3Y+106.0%

5Y+211.0%

10Y+211.0%

-15.22M

Operating Cash Flow

111%

3Y+123.0%

5Y+245.0%

10Y+245.0%

Intensity Therapeutics, Inc. Profit Bridge

INTS · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (25.00K)

Gross Profit-25.00K

Operating Expenses

Operating Expenses (16.59M)

Operating Income-16.59M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense317.00K

Pretax Income-16.27M

Income Tax (0.00)

Net Income-16.27M

Net Income

-16.27M

Profitability Analysis

Intensity Therapeutics, Inc. Income Statement

INTS • NASDAQ

Intensity Therapeutics, Inc. Income Statement	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
REVENUE
GROSS PROFIT
Cost of Revenue	(25K)	(147K)	(179K)	(0.0)	(0.0)	(0.0)
Gross Profit	-25K	-147K	-179K	0.0	0.0	0.0
OPERATING INCOME
Operating Expenses	(16.6M)	(8.2M)	(7.5M)	(8M)	(6.2M)	(5.7M)
Selling, General & Administrative	(6.1M)	(3.4M)	(2.4M)	(2.2M)	(1.2M)	(1.2M)
Research & Development	(10.5M)	(4.8M)	(5.1M)	(5.9M)	(5.1M)	(4.4M)
Operating Income	-16.6M	-8.3M	-7.6M	-8M	-6.2M	-5.7M
PRE-TAX INCOME
Interest Expense	(0.0)	(305K)	(81.8K)	(16.8K)	(0.0)	(0.0)
Net Interest Income	314K	19K	-79.3K	-14.2K	74K	0.0
Other Expenses	(0.0)	(0.0)	-98.3K	(0.0)	(0.0)	(0.0)
Total Other Income Expenses Net	317K	-2.2M	49.1K	118.1K	192.8K	295.7K
Income Before Tax	-16.3M	-10.5M	-7.6M	-7.9M	-6M	-5.4M
NET INCOME
Income Tax Expense	(0.0)	(0.0)	(0.0)	-2.6K	(0.0)	(0.0)
Net Income	-16.3M	-10.5M	-7.5M	-7.9M	-6M	-5.2M

SEC Filings

INTS - Filing history and reports

No SEC filings available for INTS

Related Guides

Blog Categories

Continue your INTS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.